4H-Pyrido[1,2-a]pyrimidine-2-carboxamide, N-[[2-[[(cyclobutylmethyl)amino]methyl]-1H-indol-6-yl]methyl]-4-oxo-
Dedifferentiated Liposarcoma
Explore 5 assets in Dedifferentiated Liposarcoma →Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
STORM Therapeutics LTD
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06975293CT.gov STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Dedifferentiated Liposarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| 4H-Pyrido[1,2-a]pyrimidine-2-carboxamide, N-[[2-[[(cyclobutylmethyl)amino]methyl]-1H-indol-6-yl]methyl]-4-oxo- (this asset) | STORM Therapeutics LTD | P1/2 | CC · 47 |
| Stc-15 | STORM Therapeutics LTD | P1/2 | CC |
| Toripalimab | STORM Therapeutics LTD | P1/2 | CC |
| okn4395 | Epkin | P1 | CC |
| tp-1287 | Sumitomo Pharma America, Inc. | P1 | CC |
| Pembrolizumab | Epkin | P1 | CC |
Other indications for 4H-Pyrido[1,2-a]pyrimidine-2-carboxamide, N-[[2-[[(cyclobutylmethyl)amino]methyl]-1H-indol-6-yl]methyl]-4-oxo-
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Leiomyosarcoma | — | P1/2 | CC · 47 |
| Sarcoma | — | P1/2 | CC · 43 |
| Cancer | — | P1 | CC · 42 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. 4H-Pyrido[1,2-a]pyrimidine-2-carboxamide, N-[[2-[[(cyclobutylmethyl)amino]methyl]-1H-indol-6-yl]methyl]-4-oxo- in Dedifferentiated Liposarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/4h-pyrido12-apyrimidine-2-carboxamide-n-2-cyclobutylmethylaminomethyl-1h-indol-6-ylmethyl-4-oxo-dedifferentiated-liposarcoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →